Navigation Links
Fox Chase researchers report that naproxen reduces tumors in a mouse model of colon cancer
Date:4/6/2011

ORLANDO, FL (April 6, 2011) Numerous studies show that non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of colon cancer. However, animal studies testing the NSAID naproxen or its derivative, NO-naproxen, have focused primarily on chemically-induced tumor formation. Now, researchers at Fox Chase Cancer Center find that naproxen and NO-naproxen reduce tumor formation in a strain of mutant mice that spontaneously develop colon tumors. The data also suggest that naproxen blocks a gatekeeper step that initiates tumor formation.

Margie Clapper, PhD, Co-Leader of the Cancer Prevention and Control Program at Fox Chase, will present the data in a late-breaking abstract session at the AACR 102nd Annual Meeting 2011 on Wednesday, April 6.

"There is a major effect on the very small lesions, about a 90% reduction in the mutant mice treated with naproxen compared with control animals," says Clapper. "That tells us this drug may be very appropriate for intervening early in people, far in advance of the development of large tumors. We might be able to have a significant impact on the very early and small lesions, thus reducing the morbidity associated with the disease."

Scientists have shown previously that both naproxen and NO-naproxen kill colon cancer cells in culture, with NO-naproxen appearing to be more powerful than naproxen. In the current study, the team fed mice genetically predisposed to spontaneously develop colon tumors either regular food or food supplemented with high- or low-dose naproxen or high- or low-dose NO-naproxen. After 45 days, they found that mice fed low-dose naproxen had 70.3% fewer small tumors than the control animals and mice fed low-dose NO-naproxen had 64.0% fewer tumors than control animals. Moreover, a 89.3% reduction in very small tumors, known as microadenomas, was observed when mice were fed high-dose naproxen.

Although Clapper and first author Wen-Chi Chang, PhD, Assistant Research Professor at Fox Chase, had expected that NO-naproxen would be a more powerful chemopreventive agent based on cell culture data, the current study indicates this is not the case in animals.

Clapper says their results, which favor naproxen, fit well with a recent decision by the U.S. Food and Drug Administration (FDA). Scientists had developed NO-naproxen with the goal of reducing gastrointestinal toxicity associated with regular use of NSAIDs. The FDA, however, declined to approve NO-naproxen saying there was not enough evidence that it was less toxic than the older drug. "Our data are highly supportive of using what is already on the market, and FDA approved for arthritis, for the prevention of cancer," Clapper says.

Chang says a key aspect of the new data is naproxen's ability to block a very early step in colon cancer formation. "If we can identify the exact mechanism that naproxen uses to block tumor formation, then, in the future, we can work with chemists to design a compound that hits that pathway, without the broad spectrum of effects and side effects seen with NSAIDs," Chang says.


'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Hollywood-Style Liposuction Comes to DC: Chevy Chase Smartlipo Brings Revolutionary Laser-Assisted Liposuction to DC Metro Area
2. Torchmark Corporation Declares Dividend and Resumes Stock Repurchases
3. International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc.
4. Grand Opening of LIFE Ionizer Australia Launches with a Free Ionizer Upgrade with Purchase of Alkaline Water Ionizer from LIFE Ionizer Australia
5. A New Twist On Convert to Purchase
6. Ensemble Healthcare Properties Purchases North Valley Medical Plaza
7. ARI Purchases Intercytex Assets
8. CapSite™ Provides Detailed Transparency on Healthcare Technology Purchases
9. Ivory Homes Plans Ahead for the April 30th Home Buyer Tax Credit Deadline with 100 New Homes Ready for Quick Purchase
10. R-Biopharm Group Purchases a Majority Ownership in Trilogy Lab, Expanding US Operations
11. Fox Chase clinical trial tests first of its kind antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... Charlevoix, MI (PRWEB) , ... February 24, 2017 ... ... venue in Charlevoix, once again hosted their Military Wedding Giveaway, with the ... be hosted by Castle Farms with services generously donated from local vendors: A ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... media outlet with a clinician-based audience, will be participating in Rare Disease Day ... in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une ... d,annoncer les excellents résultats semestriels clos le 31 décembre ... présentation complète « Résultats et mise à jour sur la ... Faits marquants ... $ ; en hausse de 104 %) Bénéfice ...
(Date:2/24/2017)... , Feb. 23, 2017  The particle ... million by 2021 from USD 275.9 million in ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... spending on pharmaceutical R&D, and growth in manufacturing ... the market growth for particle counters. On the ...
(Date:2/23/2017)... 23, 2017 Visiomed, the French leader ... 1997, is changing the landscape of healthcare with ... with pro-active, custom-made solutions. Recognizing the rising demand ... affordable healthcare without walls, Visiomed has launched BewellConnect, ... with healthcare professionals that is empowering the lives ...
Breaking Medicine Technology: